# Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia

> **NCT02215629** · PHASE1 · WITHDRAWN · sponsor: **Verastem, Inc.**

## Conditions studied

- Relapsed or Refractory Acute Myeloid Leukemia
- Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** VS-4718

## Key facts

- **NCT ID:** NCT02215629
- **Lead sponsor:** Verastem, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2016-09
- **Final completion:** 2016-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215629, "Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02215629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*